TO THE Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: TO THE Pharmaceutical Import Records from India — 11 Products, $930.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

TO THE — Pharmaceutical Importer Profile (2026) | 11 Products, $930.0K Trade | TransData Nexus

TO THE

Pharmaceutical Importer · Brazil · Advanced Diabetes Medications Focus · $930.0K Total Trade · DGFT Verified

TO THE is a pharmaceutical importer based in Brazil with a total trade value of $930.0K across 11 products in 4 therapeutic categories. Based on 195 verified import shipments from Indian Customs (DGFT) records, TO THE is the #1 buyer in 1 product including Ibrutinib. TO THE sources from 2 verified Indian suppliers, with Ganpati Exim Inc accounting for 65.8% of imports.

TO THE — Import Portfolio & Supplier Network

TO THE import network — 11 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to TO THE?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Ganpati Exim Inc	$5.4M	2,163	65.8%
Vinayak Pharma Corp	$2.8M	1,056	34.2%

TO THE sources from 2 verified Indian suppliers across 894 distinct formulations. Total import value: $8.2M across 3,219 shipments.

Formulation	Value	Ships
Pharmaceutical product (medicine)	$3.2M	1,340
Pharmaceutical product (medicine)	$586.2K	228
Pharmaceutical product (medicine):Pack	$506.6K	177
Pharmaceutical product (medicine)	$353.7K	109
Pharmaceutical product (medicine)	$125.2K	52
Pharmaceutical product (medicine) : packof 100 TAB dutasteride 0.5 MG	$89.0K	3
Pharmaceutical product (medicine) : Pack of 100 TAB dutasteride tablets 0.5 MG	$84.5K	3
Pharmaceutical product (medicine) : packof 1 bimatoprost ophthalnic 0.03% 3 ML	$77.0K	5
Pharmaceutical product (medicine) : packof 21 TAB levonorgestrel and ethinyloestradial tablets 0.05+0.03 MG	$65.0K	2
Pharmaceutical product (medicine) : packof 21 TAB levonorgestrel ethinyloestradial tablets 0.05+0.03 MG	$64.8K	2
Pharmaceutical product (medicine) : Pack of 10 TAB semaglutide tablets 14MG	$59.4K	4
Pharmaceutical product (medicine) :packof 21 TAB levonorgestrel and ethinyloestradial tablets 0.05+0.03 MG	$54.5K	2
Pharmaceutical product (medicine) : packof 150 cap dutasteride soft gelatincapsules 0.5 MG	$50.4K	8
Pharmaceutical product (medicine) : (Pack of 100 TAB dutasteride tablets 0.5 MG)	$50.0K	1
Pharmaceutical product (medicine) : Pack of 21 TAB levonorgestrel ethinyloestradial tablets 0.05+0.03 MG	$50.0K	1

Import Portfolio — Top 11 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Cyclophosphamide	Oncology	$209.4K	8	1.1%	8
2	Semaglutide	Advanced Diabetes Medications	$207.7K	24	4.2%	8
3	Ibrutinib	Advanced Oncology	$190.3K	52	14.2%	1
4	Empagliflozin	Diabetes & Endocrine	$78.2K	13	1.2%	18
5	Linagliptin	Advanced Diabetes Medications	$78.2K	13	2.0%	3
6	Canagliflozin	Advanced Diabetes Medications	$56.1K	5	6.4%	5
7	Actinomycin	Advanced Oncology	$32.9K	48	0.9%	6
8	Osimertinib	Advanced Oncology	$32.6K	7	1.6%	5
9	Daratumumab	Advanced Oncology	$31.9K	9	2.4%	8
10	Pomalidomide	Advanced Oncology	$10.9K	13	0.2%	10
11	Cabozantinib	Advanced Oncology	$1.8K	3	1.4%	10

TO THE imports 11 pharmaceutical products across 4 categories into Brazil totaling $930.0K. The company is the #1 buyer for 1 product: Ibrutinib.

TO THE — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

TO THE is a Brazilian pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Operating as a key player in Brazil's pharmaceutical distribution network, TO THE sources a diverse range of products to meet the country's healthcare needs. The company is headquartered in Brazil and functions as an independent entity without a publicly known parent company. Its role in the Brazilian pharmaceutical supply chain involves importing and distributing a variety of pharmaceutical products, thereby contributing to the availability of essential medications across the nation.

2Distribution Network

While specific details about TO THE's warehouse locations and logistics capabilities are not publicly disclosed, the company is known to import a wide array of pharmaceutical products from India. This extensive importation suggests a well-established distribution network capable of handling diverse product categories. TO THE's geographic coverage likely spans major urban centers and healthcare facilities throughout Brazil, ensuring that imported medications are accessible to a broad segment of the population.

3Industry Role

In Brazil's pharmaceutical supply chain, TO THE operates primarily as an importer and distributor of finished pharmaceutical formulations. The company's activities involve sourcing medications from international suppliers, particularly from India, and facilitating their distribution within Brazil. This role is crucial in ensuring the availability of a wide range of pharmaceutical products to meet the diverse healthcare needs of the Brazilian population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — TO THE

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

TO THE's sourcing strategy exhibits a high degree of concentration, with the majority of its pharmaceutical imports originating from two Indian suppliers: GANPATI EXIM INC and VINAYAK PHARMA CORP. GANPATI EXIM INC accounts for 65.8% of the total shipments, while VINAYAK PHARMA CORP contributes 34.2%. This dual-supplier model indicates a strategic choice to maintain strong, focused relationships with key suppliers, potentially leading to favorable terms and streamlined logistics. However, such concentration also introduces risks; any disruptions with these suppliers could significantly impact TO THE's ability to meet market demand. The stability of these relationships is critical, and the company's reliance on a limited number of suppliers underscores the importance of effective supplier management and contingency planning.

2Supply Chain Resilience

TO THE's supply chain resilience is closely tied to its reliance on two primary Indian suppliers. The company's importation of 894 unique pharmaceutical formulations suggests a diverse product portfolio, which can mitigate risks associated with dependency on a limited number of suppliers. However, the heavy reliance on GANPATI EXIM INC and VINAYAK PHARMA CORP means that any disruptions in their operations—such as production delays, quality issues, or regulatory challenges—could have a substantial impact on TO THE's ability to supply the Brazilian market. To enhance resilience, TO THE may consider diversifying its supplier base and establishing contingency plans to address potential supply chain disruptions.

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the pharmaceutical industry is regulated by the National Health Regulatory Agency (ANVISA), an autonomous agency under the Ministry of Health. ANVISA is responsible for ensuring the safety, efficacy, and quality of health products, including pharmaceuticals. The agency oversees the registration, importation, and commercialization of pharmaceutical products, establishing standards and guidelines that companies must adhere to. Key legislation governing pharmaceutical imports includes Law No. 6,360/1976, which regulates the sanitary surveillance of medicines, drugs, pharmaceutical inputs, and related products in Brazil. This law outlines the procedures and requirements for the importation of medicines, ensuring that imported products meet the necessary health standards. Additionally, ANVISA's Resolution RDC 753/2022 provides specific guidelines for the registration of new synthetic and semi-synthetic drugs, as well as generic and similar drugs, detailing the requirements for market authorization and post-marketing surveillance. (gov.br)

2Import Licensing & GMP

Importers of pharmaceutical products into Brazil must obtain an Import Authorization (AI) from ANVISA before the shipment reaches the country. This authorization ensures that the imported products comply with Brazilian health regulations and are registered with ANVISA. Importers are also required to provide proof of Good Manufacturing Practices (GMP) compliance, demonstrating that the products were manufactured in facilities adhering to internationally recognized quality standards. ANVISA's Resolution RDC 658/2022 outlines the general GMP guidelines for medicines, aligning with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) standards to ensure product quality and safety. (gov.br)

TO THE — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

TO THE's product strategy focuses on importing medications in the therapeutic areas of advanced diabetes and oncology. The company's top five imported products include cyclophosphamide, semaglutide, ibrutinib, empagliflozin, and linagliptin, which are integral to the treatment of these conditions. The significant import values and market shares of these products indicate a strong demand within Brazil for advanced treatments in these therapeutic categories. This focus aligns with the global trend of increasing prevalence of chronic diseases such as diabetes and cancer, driving the need for specialized and effective therapies.

2Sourcing Profile

TO THE's sourcing strategy is centered on importing generic drugs from India, a major global supplier of affordable and high-quality pharmaceuticals. The company's preference for finished pharmaceutical formulations allows for quicker market entry and compliance with Brazilian regulations, as these products are already manufactured and ready for distribution. India's well-established pharmaceutical industry, with its adherence to international quality standards, makes it a reliable source for TO THE's procurement needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to TO THE

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Brazilian market by partnering with TO THE. The company's concentrated sourcing strategy indicates a potential openness to diversifying its supplier base, especially if new suppliers can offer competitive pricing, reliable quality, and the ability to meet the diverse product requirements of the Brazilian market. Gaps in TO THE's current sourcing may include specific formulations or therapeutic areas not currently covered, presenting opportunities for suppliers to fill these niches.

2Requirements & Qualifications

Indian exporters seeking to supply TO THE and the Brazilian market must ensure that their products are registered with ANVISA and comply with Brazilian health regulations. This includes obtaining the necessary import authorizations, providing proof of GMP compliance, and ensuring that products meet labeling and stability requirements. Additionally, exporters must be prepared to navigate the regulatory processes for product registration and importation, which may involve coordination with local partners in Brazil.

3How to Approach

Frequently Asked Questions — TO THE

What products does TO THE import from India?

TO THE imports 11 pharmaceutical products across 4 categories. Top imports: Cyclophosphamide ($209.4K), Semaglutide ($207.7K), Ibrutinib ($190.3K), Empagliflozin ($78.2K), Linagliptin ($78.2K).

Who supplies pharmaceuticals to TO THE from India?

TO THE sources from 2 verified Indian suppliers. The primary supplier is Ganpati Exim Inc (65.8% of imports, $5.4M).

What is TO THE's total pharmaceutical import value?

TO THE's total pharmaceutical import value from India is $930.0K, based on 195 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does TO THE focus on?

TO THE imports across 4 categories. The largest: Advanced Diabetes Medications (36.8%), Advanced Oncology (32.3%), Oncology (22.5%).

Get Full TO THE Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.